Diarylquinoline TMC207 as potential new therapy for multidrug-resistant tuberculosis
- Correspondence to Dr E Tevendale, CMT1, St James University Hospital, Leeds, UK;
TMC207 is an investigational diarylquinoline which inhibits mycobacterial ATP synthase in drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro. It is bactericidal to dormant tubercle bacilli, therefore offering a new mechanism for the treatment of multidrug-resistant tuberculosis.
This study is the first stage of a phase 2 randomised controlled trial. Conducted in South Africa, newly …